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I M M U N O L O G Y
Global and local envelope protein dynamics of hepatitis 
C virus determine broad antibody sensitivity
Elias H. Augestad1, Matteo Castelli2, Nicola Clementi2, Luisa J. Ströh3, Thomas Krey3,4,5,6,7, 
Roberto Burioni2, Nicasio Mancini2, Jens Bukh1, Jannick Prentoe1*
Broad antibody sensitivity differences of hepatitis C virus (HCV) isolates and their ability to persist in the presence 
of neutralizing antibodies (NAbs) remain poorly understood. Here, we show that polymorphisms within glyco-
protein E2, including hypervariable region 1 (HVR1) and antigenic site 412 (AS412), broadly affect NAb sensitivity 
by shifting global envelope protein conformation dynamics between theoretical “closed,” neutralization- 
resistant and “open,” neutralization-sensitive states. The conformational space of AS412 was skewed toward 
-hairpin–like conformations in closed states, which also depended on HVR1, assigning function to these enigmatic 
E2 regions. Scavenger receptor class B, type I entry dependency of HCV was associated with NAb resistance 
and correlated perfectly with decreased virus propensity to interact with HCV co-receptor CD81, indicating 
that decreased NAb sensitivity resulted in a more complex entry pathway. This link between global E1/E2 states 
and functionally distinct AS412 conformations has important implications for targeting AS412 in rational HCV 
vaccine designs.
INTRODUCTION
A vaccine against hepatitis C virus (HCV) is urgently needed (1) 
and should induce neutralizing antibodies (NAbs) against the HCV 
envelope proteins 1 (E1) and 2 (E2), which form the E1/E2 heterodimer 
on virus particles and mediate entry. E2 has been shown to interact 
with HCV entry co-receptors, including the tetraspanin CD81 for 
translocation to the cell tight junction, as well as with scavenger recep-
tor class B, type I (SR-BI) (2). HCV NAb sensitivity might be governed 
by intrinsic molecular and structural features of E1/E2 (3, 4).
The N-terminal part of E2, termed hypervariable region 1 (HVR1; 
Fig. 1A), plays an important role in NAb evasion, and it was initially 
suggested to provide NAb protection by sterically occluding the 
CD81 binding site on E2 (5). However, a much wider breadth in 
protected epitopes was later described, making this hypothesis less 
likely (6). Most recently, we observed that E2 N-linked glycans do 
not modulate NAb sensitivity in the absence of HVR1, suggesting 
an indirect role in NAb protection (7). HVR1-mediated NAb pro-
tection has been validated in vivo (8), but the mechanism remains 
a conundrum in two parts. First, a majority of the 27 positions of 
HVR1 rapidly accumulates amino acid changes. This is believed to 
be due to positive selection from HVR1-specific antibodies (9), but 
it remains unclear how these changes affect its NAb-protective 
functions. Second, HVR1 sits immediately upstream of antigenic 
site 412 (AS412; Fig. 1A). While the AS412 sequence is highly con-
served, it is extremely flexible and x-ray crystal structures of NAbs 
bound to AS412 peptides have shown that it can adopt widely dif-
ferent conformations (from a -hairpin to an extended conforma-
tion) (10). HCV E2 monomeric structures with various N- and 
C-terminal truncations have been solved, and these have either not 
included AS412 or yielded conflicting evidence on its orientation 
(11–14). Thus, a central question arises of how HVR1 overcomes 
extreme inherent sequence diversity and E1/E2 orientation restric-
tions, imposed by conformation-divergent AS412, to consistently 
protect such a wide range of NAb epitopes. The high sequence con-
servation of AS412 and the fact that it is a linear epitope enable many 
types of antigen mimics for vaccine development (15–17). Last, NAbs 
targeting the AS412 -hairpin conformation have shown efficacy 
in vivo (18), further increasing AS412 interest as a prime vaccine 
target. However, AS412 antibodies are rare in patients (19), and many 
groups have proposed that AS412 flexibility is a viral mechanism to 
curb development of effective NAbs in infected patients (4, 10).
Here, we use an in-depth reverse-genetics approach on cell 
culture–infectious HCV (HCVcc) with fully functional E1/E2 from 
multiple isolates and genotypes to define polymorphic positions 
within and outside of HVR1 that determine NAb sensitivity across 
diverse NAb epitopes. Temperature-dependent neutralization ex-
periments with monoclonal antibodies (mAbs) and Fabs showed 
how residues at these positions regulate NAb sensitivity by perturb-
ing global conformation dynamics of the HCV envelope glyco-
proteins, involving a theoretical neutralization-sensitive “open” state 
of E1/E2, favored at high temperatures, and a neutralization-resistant 
“closed” state of E1/E2, favored at low temperatures, of which the 
stability of the latter depended on the presence of HVR1. Further-
more, performing virus neutralization and entry blocking assays, 
we observed perfect correlation between increased SR-BI entry depen-
dency and decreased propensity to interact with CD81, suggesting 
that HCV can continuously modulate NAb sensitivity at the expense 
of a more complicated entry pathway. Last, we demonstrated that 
the conformational space of AS412 was skewed toward -hairpin–
like conformations in the closed E1/E2 state, linking the local struc-
tural flexibility of AS412 to global E1/E2 conformational states and 
NAb evasion. Thus, our study provides mechanistic insights into 
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dynamic E1/E2 features that regulate broad NAb sensitivity and 
entry and into AS412 functionality with important implications for 
targeting AS412 epitopes in rational vaccine design.
RESULTS
NAb protection conferred by diverse HVR1s was mainly 
determined by its C-terminal polymorphic heterogeneity
Using HCVcc with full-length wild-type E1/E2 sequence (FL) of 
genotype 1a isolate H77 (H77-FL) (20), we generated chimeric 
viruses with HVR1 from isolates of genotypes 1 to 6 (21–26). We 
found that HVR1 from other HCV isolates had divergent effects on 
infectivity in Huh7.5 cells (fig. S1, A and B). To examine the effect 
of HVR1 from different isolates on H77 NAb resistance, we generated 
envelope protein sequence-confirmed first-passage virus stocks of 
H77-FL and viable HCVcc with HVR1 from genotype 1 to 4 isolates 
(Fig. 1A). Testing neutralization sensitivity against the human 
mAbs AR3A, AR4A, and AR5A (27, 28), we observed that HVR1 
from TN (genotype 1a), J6 (genotype 2a), S52 (genotype 3a), and 
ED43 (genotype 4a) decreased neutralization sensitivity at statisti-
cally significant levels (Fig. 1B). The magnitude of these differences 
varied greatly across the tested epitopes, suggesting the presence of 
epitope-specific levels of HVR1-mediated protection.
Next, we investigated which part of HVR1 was involved in the 
observed differences in HVR1-mediated NAb protection. TN-HVR1 in 
the H77 backbone increased AR4A resistance ~50-fold and differed 
from H77-HVR1 at 7 of 27 amino acid positions. Thus, we introduced 
each of the seven TN polymorphisms into H77-FL. Performing AR4A 
neutralization, we found that F403 or S404 significantly increased 
resistance, in addition to a minor but significant increase by Y386 
(Fig. 1C). Furthermore, we found that A400 and S401 had an effect 
when present in combination and that the introduction of A400, 
S401, F403, and S404 into H77-FL (H77TN_400–404) reproduced the 
neutralization-resistant phenotype of H77TN_HVR1 (Fig. 1C). The ef-
fect of heterogeneity within positions 400 to 404 was confirmed by 
testing each of the seven H77 polymorphisms in H77TN_HVR1 (fig. S1C).
To test whether this C-terminal part of HVR1 was generally re-
sponsible for modulating NAb resistance of HCV, we introduced 
Fig. 1. NAb sensitivity of HCV is regulated by polymorphisms within positions 400 to 404 in HVR1. (A) Alignment of the N-terminal part of the E2 protein against 
genotype 1a H77 reference genome (GenBank accession no. AF009606) for HCV isolates of genotypes 1 to 4 (Mega 7), identical with the H77C genome used in the present 
study. Dots indicate homology with H77. (B to D) Neutralization by the human monoclonal NAbs AR3A (B and D), AR4A (B to D), and AR5A (B and D) of the indicated HCVcc 
recombinants. The data were analyzed using three-parameter dose-response regression to calculate median inhibitory concentration (IC50) values and 95% confidence 
intervals (GraphPad Prism 8.0.0). *HCVcc recombinants with the same combinations of TN polymorphisms (TN_400–404 used in subsequent figures). TM, transmembrane 
domain; Stem, a stalk-like structure that connects the rest of the E2 ectodomain with the TM.
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positions 400 to 405 from S52 and ED43 into H77-FL (S52 and 
ED43 differed from H77 at the additional position 405; Fig. 1A). 
Testing sensitivity against the NAbs AR3A, AR4A, and AR5A, we 
observed that the full-length HVR1 sequence from TN, S52, and 
ED43 conferred similar levels of neutralization resistance compared 
with TN-HVR1400–404, S52-HVR1400–405, and ED43-HVR1400–405, 
respectively (Fig. 1D). Thus, our data indicated that HVR1 posi-
tions 400, 402, 403, and 404, with a possible role of position 405, 
were the primary HVR1 determinants of broad NAb protection.
Broad neutralization sensitivity of HCV was determined by 
the E2 N-terminal front layer and HVR1
We tested the effects of swapping HVR1 between HCVcc with E1/
E2 sequence from other HCV isolates. Thus, we generated all possible 
reciprocal HVR1 swaps between H77, TN, and S52 HCVcc. Using 
AR3A and AR4A, we found that, in all tested E1/E2 backgrounds, 
H77-HVR1 conferred relatively lower NAb protection compared 
with TN-HVR1 and especially S52-HVR1, showing that the relative 
contributions of a specific HVR1 were not E1/E2 background specific 
(Fig. 2A). However, using one-way analysis of variance (ANOVA), 
we found that the absolute level of NAb protection conferred by 
either H77-, TN-, and S52-HVR1 was significantly different be-
tween the different E1/E2 backgrounds and that the H77 back-
ground was intrinsically more resistant than TN and S52 (fig. S2A). 
To address which part of E1 or E2 contributed to NAb sensitivity 
differences, we generated envelope chimeras of H77 and TN in 
which E1, E2 downstream of HVR1 (residues 411 to 746), or the 
N-terminal part of E2 downstream of HVR1 (the front layer, spanning 
residues 411 to 461) from TN was introduced into H77TN_HVR1. 
Testing sensitivity against AR3A and AR4A, we found the determi-
nants of protection to be located within position 411 to 461 of E2 
(fig. S2B). Next, we tested the effect of introducing each of the six 
TN polymorphisms of this region into E2 of H77TN_HVR1. We found 
that H77TN_HVR1/P453S significantly decreased resistance against both 
AR3A and AR4A compared to H77TN_HVR1, whereas H77TN_HVR1/I414V 
decreased AR4A resistance and H77TN_HVR1/E431D decreased AR3A 
resistance (Fig. 2B and fig. S2C). In combination, V414, D431, and 
S453 were sufficient to eliminate NAb sensitivity differences between 
H77 and TN E1/E2 backgrounds (Fig. 2B and fig. S2C). This phenom-
enon was HVR1 dependent as the introduction of V414, D431, and 
S453 into H77HVR1 had no impact on neutralization sensitivity to 
AR3A and AR4A (Fig. 2B and fig. S2D).
Envelope protein polymorphisms alter NAb sensitivity by 
affecting global envelope conformation dynamics
We generated H77 HCVcc with the identified NAb-sensitizing TN 
polymorphisms at positions 414, 431, and 453 introduced into H77-
FL (H77TN_414/431/453) or in combination with the protective HVR1 TN 
polymorphisms at positions 400, 401, 403, and 404 (H77TN-comb). 
Testing H77-FL, H77TN_400–404, H77TN_414/431/453, and H77TN-comb 
against a wide range of monoclonal NAbs, we observed epitope-specific 
antibody sensitivity differences of 70- to 2000-fold comparing the 
most sensitive virus (H77TN_414/431/453) with the most resistant virus 
(H77TN_400–404) (Fig. 3A). The large differences in broadly neutral-
izing antibody (bNAb) sensitivity of these combinations of polymor-
phisms simplified further analyses, and these observations led us to 
examine whether a mechanism involving perturbation of global con-
formation dynamics of the HCV envelope glycoproteins could be 
involved. We hypothesized the existence of theoretical open states 
of E1/E2 (characterized by increased neutralization sensitivity due to 
broad exposure of conserved NAb epitopes), and theoretical closed 
states of E1/E2 (characterized by neutralization resistance as these 
epitopes are less exposed). Such open/closed state dynamics have 
been described using x-ray scattering of proteins in solution (29) as 
well as for virus-associated envelope proteins for flaviviruses, in-
cluding West Nile virus and dengue virus (30). It is clear from 
these studies that increased temperature favor open protein states. 
Thus, we assessed AR3A and AR4A sensitivity of H77-FL, H77TN_400–404, 
H77TN_414/431/453, and H77TN-comb at 4°, 37°, and 40°C (Fig. 3B). Tem-
perature-dependent increases in virus sensitivity were observed for 
both NAbs. In contrast, this was not the case for H77∆HVR1 and 
H77∆HVR1,TN_414/431/453. For the most sensitive virus retaining HVR1, 
H77TN_414/431/453, the median inhibitory concentration (IC50) values at 
the higher temperatures grouped close to what was observed for 
H77∆HVR1, suggesting that HVR1-deleted viruses represented a limit 
in these assays and supports our hypothesis that the E1/E2 dynamics 
was intrinsically skewed toward open, neutralization-sensitive, states 
for virus without HVR1.
Next, we produced H77-FL, H77TN_400–404, H77TN_414/431/453, and 
H77TN-comb soluble E2 ectodomains (sE2, amino acids 384 to 645) 
and performed AR3A-binding enzyme-linked immunosorbent assays 
(ELISA), which showed that polymorphisms outside of HVR1 did 
influence AR3A binding, although to a lesser extent than the same 
polymorphisms in E1/E2 on virus particles (10-fold effect versus 
100-fold effect; Fig. 3, A and C). Polymorphisms outside of HVR1 
did not significantly influence binding of sE2 with a different 
E2-specific bNAb, HC84.26 (fig. S3C), possibly reflecting that the 
effect of these polymorphisms on virus-associated E1/E2 binding 
was much smaller for HC84.26 than for AR3A (Fig. 3A). Poly-
morphisms in HVR1 affected neither AR3A nor HC84.26 binding, 
indicating that HVR1 function was not fully recapitulated on sE2 
(Fig. 3C and fig. S3C).
These discrepancies and the fact that published E2 structures 
lack the complete HVR1-AS412 sequence and disagree on AS412 
orientation indicate that critical components of HVR1-AS412 in-
teractions cannot be studied on sE2 alone. Conversely, amino acid 
positions 431 and 453 did regulate sE2 AR3A binding and reside 
well within pedigreed parts of multiple published E2 structures 
(11–14). Thus, we assessed their effects by performing molecular 
dynamics (MD) simulations of a truncated E2 core (residues 421 to 
647; Fig. 1A) of H77 (H77-E2c) and H77TN_431/453 (H77-E2cTN_431/453), 
which showed differences in front layer flexibility (Fig. 3D and 
fig. S3D) and a different exploration of the conformational space. 
Performing principal components analysis (PCA) followed by Gibbs 
free energy landscape (FEL) calculations (31) on both MD trajectories, 
we observed that H77-E2c mainly explored two conformations, 
conf. #1 and conf. #2, while H77-E2cTN_431/453 mainly explored one 
conformation, superimposable on H77-E2c conf. #2 (Fig. 3E and 
fig. S3E). N-terminal protein orientation differed between H77-
E2cTN_431/453 and H77-E2c conf. #1, supporting a direct role in 
controlling the motions of the HVR1-AS412 regions immediately 
upstream. We also ran MD simulations and calculated the front layer 
flexibility and dynamics of TN-E2c and S52-E2c (Fig. 3F and fig. S3, 
D and E). Both mainly visited conformations highly similar to H77-
E2c conf. #2 and H77-E2cTN_431/453, which fits with well with our 
observations that for HVR1-swapped viruses sharing the same 
HVR1, the TN and S52 E1/E2 backgrounds were intrinsically less 
resistant than H77 (fig. S2A). Last, by calculating the solvent-accessible 
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surface area (SASA) of AR3A epitopic residues (residues 427, 429, 
431, 438 to 439, 442 to 443, 529, and 531) from MD simulations, we found 
that the AR3A epitope was more exposed for H77-E2cTN_431/453 
than H77-E2c, confirming the AR3A ELISA data (Fig. 3G). Together, 
this provides an interesting hypothesis in which E2 front layer dynam-
ics play a central role in open/closed E1/E2 protein dynamics.
NAb resistance of HCV conferred increased dependency 
on SR-BI to mediate critical CD81 interactions
We next examined whether the identified conformation dynamics 
of the HCV envelope described in this study were linked to viral 
entry. Thus, to test the effects on HCV entry receptor dependency, 
we performed dose-response blocking of H77-FL, H77TN_400–404, 
H77TN_414/431/453, and H77TN-comb entry using antibodies against 
HCV co-receptors CD81, low density lipoprotein receptor (LDLr), and 
SR-BI. While all viruses depended equally on CD81 and LDLr 
(Fig. 4, A and B), NAb resistance appeared to be linked with increased 
SR-BI entry dependency, with the resistant H77TN_400–404 being most 
dependent (Fig. 4C). Performing pre- and postattachment receptor 
blocking of CD81 and SR-BI, we observed no role of either receptor 
in cell attachment (Fig. 4D). Given the evidence supporting a 
sequential interaction of HCV with SR-BI followed by CD81 (2), 
we wanted to examine the propensity of E1/E2 that favored open or 
closed states to interact with CD81. Thus, we performed virus neutral-
ization of these same viruses using soluble CD81 large extracellular 
loop (sCD81-LEL; Fig. 4E). Plotting the correlation between SR-BI 
dependency and sensitivity to neutralization with sCD81-LEL, we 
observed near-perfect correlation (R2 = 0.98), supporting a role of 
SR-BI in mediating critical CD81 interactions of NAb-resistant HCV 
for which E1/E2 favor closed states (Fig. 4F). However, we found no 
significant effect of the TN polymorphisms on sCD81-LEL binding 
of sE2 in ELISA (fig. S4A), once again highlighting that the effects of 
these polymorphisms on protein dynamics are not fully recapitulated 
on sE2. Performing correlation plots of SR-BI entry dependency and 
Fig. 2. Global NAb sensitivity of HCV is regulated by polymorphisms both within and outside of HVR1. (A and B) Neutralization by the human monoclonal NAbs 
AR3A and AR4A of HVR1-swapped H77-, TN-, and S52-based recombinants (A) or H77-based recombinants with TN polymorphisms (B). The data were analyzed as 
described in Fig. 1B. Differences between IC50 values were compared in two-tailed t tests (GraphPad Prism 8.0.0) with Welch’s correction. Testing was done at the 95% 
confidence level and corrected for multiple testing by adjusting the P value accordingly (tested P values, 0.017). *Neutralization sensitivity was statistically significantly 
different. n.s., neutralization sensitivity was not statistically significantly different.
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virus resistance to NAbs showed consistently strong correlations 
(R2 = 0.61 to 0.98; Fig. 4G and fig. S4B) that were, with the exception 
of AR3A, inferior to sCD81-LEL. Thus, decreased propensity of HCV 
to interact with CD81-LEL correlated with NAb resistance and cor-
related perfectly with SR-BI entry dependency. This correlation indi-
cated a direct role of SR-BI in inducing a conformational change in 
E1/E2 to an open state poised for CD81 engagement during viral entry.
The conformational space of AS412 is skewed toward 
-hairpin–like conformations in closed HCV E1/E2 states
Given that HVR1 served a critical role in stabilizing closed neutralization- 
resistant E1/E2 states, we hypothesized that the local conformation 
of AS412, immediately downstream of HVR1 (Fig. 1A), would in-
fluence this. The mAbs HC33.4, AP33, and 3/11 recognize a V-shaped, 
a -hairpin, and an extended conformation of AS412, respectively 
(10). However, performing neutralization assays with the mAbs 3/11, 
HC33.4, and AP33 against H77-FL, H77TN_400–404, H77TN_414/431/453, 
and H77TN-comb (Fig. 5A), as well as the AS412 mutant virus 
H77TN_414 (fig. S5A), we reproduced the open/closed pattern observed 
for all other NAbs (Fig. 5A versus Fig. 3A). We speculated that local 
differences in the AS412 conformational space between open and 
closed E1/E2 states might be concealed by the inherent differences in 
global epitope availability. We therefore performed neutralization 
using Fab3/11, FabHC33.4, and FabAP33, which, because of their smaller 
size, might better penetrate closed E1/E2 states (fig. S5B). As 
previously described (19), mAb3/11 and Fab3/11 were poor neutralizers 
and were excluded from further analysis (Fig. 5A and fig. S5, A and B).
Calculating Fab:mAb IC50 molar ratios for HC33.4 (Fig. 5B), we 
found no significant differences between the H77 recombinants. How-
ever, the AP33 IC50 ratio of the most NAb-resistant recombinant 
Fig. 3. Protective envelope polymorphisms within positions 400 to 404 in HVR1 or outside HVR1 at positions 414, 431, and 453 influence global E1/E2 confor-
mation dynamics. (A) Neutralization using the indicated NAbs of H77 HCVcc recombinants. (B) Neutralization of H77 HCVcc recombinants performed at 4°, 37°, or 
40°C. Data were analyzed as described in Fig. 1, except that four-parameter dose-response regression was used in (B). H77TN_400–404 and H77TN-comb harbored N391S, which 
increased viral infectivity without affecting neutralization (fig. S3, A and B). (C) sE2 binding to AR3A (positions 384 to 645; see Fig. 1A) in ELISA. Values are means of dupli-
cates ± SD. OD450, optical density at 450 nm. (D) Peptide backbone residue flexibility [root mean square fluctuation (RMSF)] was calculated for all  carbons along 500-ns 
MD simulations of H77-E2c and H77-E2cTN_431/453 (positions 421 to 647); residues 421 to 535 are depicted (full RMSF plots; see fig. S3D). E2 front layer (positions 421 to 461) 
highlighted in color. (E and F) The two most visited conformations of H77-E2c compared to the main conformation of H77-E2cTN_431/453 (E), TN-E2c (F), or S52-E2c (F), all 
identified by PCA and FEL calculation on the first two principal PCs (see fig. S3E). (G) Exposure of the AR3A epitope in H77-E2c and H77TN_431/453-E2c during 500-ns MD 
simulation by computing the SASA of AR3A epitope residues.
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Fig. 4. Polymorphisms that protect HCV from NAbs also increase the need for SR-BI to mediate subsequent CD81 interactions. (A to C) Receptor blocking of the 
entry of indicated HCV recombinants using a dilution series of antibody against CD81 (A), LDLr (B), and SR-BI (C). (D) Receptor blocking of the entry of indicated recombi-
nants pre- and postviral attachment. (E) Neutralization of the indicated H77 recombinants with a dilution series of sCD81-LEL. (F) IC50 values against sCD81-LEL for the 
indicated H77 recombinants plotted against SR-BI entry dependency calculated as outlined in (C) (Bmax). The data were analyzed as described in Fig. 1 to estimate max-
imum attainable effect, Bmax (C), or to calculate IC50 values (E). (G) R2 values from IC50 values for the indicated monoclonal NAbs against H77 recombinants from (A) to (F) 
plotted against their corresponding SR-BI entry dependency calculated as outlined in (C) (Bmax) (see fig. S4B for correlation plots). All error bars represent SD. *Receptor 
blocking or neutralization sensitivity of the HCV recombinant was statistically significantly different from H77-FL.
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(H77TN_400–404) was significantly lower than for H77-FL (3.1-fold lower), 
whereas the opposite was true for the most sensitive recombinant 
(H77TN_414/431/453; 10-fold higher). Thus, -hairpin–like conforma-
tions were more prevalent in closed E1/E2 states (a relative increase 
in Fab versus mAb potency) and less prevalent in open states (a rela-
tive decrease in Fab versus mAb potency). In addition, H77TN-comb 
and H77TN_414 both had significantly lower Fab:mAb AP33 IC50 
ratios than H77TN_414/431/453 (3.4-fold and 2.6-fold, respectively), 
supporting that all polymorphisms causing global NAb resistance, 
irrespective of whether they were found in HVR1, AS412, or the E2 
Fig. 5. The conformational space of AS412 is skewed toward -hairpin–like conformations in closed HCV E1/E2 states. (A) Neutralization using the mAb 3/11, 
HC33.4, or AP33 of indicated H77 HCVcc recombinants. Data were analyzed as described in Fig. 1. (B) Ratio of Fab:mAb neutralization IC50 values for HC33.4 and AP33 of 
the indicated H77 recombinants [values calculated from fig. S5 (A and B) dose-response data]. The ratios were compared in two-tailed t tests (GraphPad Prism 8.0.0) with 
Welch’s correction. Testing was done at the 95% confidence level (*P < 0.05, **P < 0.01, and ***P < 0.001), and the P value was adjusted for multiple testing (*P < 0.025, 
**P < 0.005, and ***P < 0.0005). (C) Ribbon structures of the most-visited conformations of HVR1-AS412 systems (residues 384 to 426) based on PCA performed on 
backbone atoms from MD simulations followed by FEL calculations. AS412 is highlighted in green. Residue G418, at the AS412 -hairpin apex, is highlighted in red. 
(D and E) Neutralization by HC33.4 and AP33 Fabs against the indicated H77 HCVcc recombinants (D) or HCVcc recombinants with E1/E2 of J4, J6, J8, S52 (E) at 37° or 
40°C. Data were analyzed as described in Fig. 1, except using four-parameter dose-response regression (see fig. S6 for dose-response curves).
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front layer, shifted the AS412 conformational space toward -hairpin–
like conformations.
As HVR1-AS412 function could not be recapitulated on sE2 
experimental structures, we tested differences in AS412 exploration 
of the conformational space by performing HVR1-AS412 peptide 
(amino acids 384 to 426) structural reconstruction and MD simula-
tions of H77-FL, H77TN_400–404, H77TN_414, and H77TN_400–404/414, 
representing different NAb sensitivity phenotypes. Peptides of H77-
FL and the NAb-resistant H77TN_400–404 stably showed AS412 in a 
-hairpin conformation, involved in a -sheet with the N-terminal 
residues of HVR1 (Fig. 5C). For H77TN_414, which corresponded 
to a more NAb-sensitive phenotype than H77-FL, the AS412 - 
hairpin conformation was destabilized, but it was restored in 
H77TN_400–404/414, supporting that positions 400 to 404 influenced 
AS412 conformation by counterbalancing the -hairpin disruptive 
effect of I414V. Using the most prevalent structure as a starting 
point, we performed high-temperature unfolding experiments for 
each peptide. This showed that H77TN_400–404, which corresponded 
to the most NAb-resistant phenotype, had a more stable AS412 
-hairpin conformation (fig. S5C).
To further validate that the AS412 conformational space was 
skewed toward -hairpin–like conformations in closed E1/E2 states, we 
performed neutralization of H77-FL, H77TN_400–404, H77TN_414/431/453, 
H77TN-comb, and H77TN_414 using FabHC33.4 and FabAP33 at 37° and 
40°C. For FabHC33.4, we observed increased sensitivity at 40°C 
(Fig. 5D and fig. S6), which agreed with our findings using AR3A 
and AR4A NAbs (Fig. 3B). However, as predicted, we observed the 
opposite for FabAP33, which was more potent at 37°C than at 40°C. 
This was also observed for HCVcc recombinants with E1/E2 of isolates 
J4 (genotype 1b), J6 (2a), J8 (2b), and S52 (3a) (Fig. 5E and fig. S6), 
demonstrating that this effect was not limited to H77. Together, our 
results strongly indicated that the AS412 conformational space was 
skewed toward -hairpin–like conformations in closed E1/E2 states.
DISCUSSION
Understanding the recognized ability of HCV to evade NAbs is of 
paramount importance for any attempts at rational vaccine devel-
opment. This study shows how E2 polymorphisms encompassing 
positions 400 to 404 in HVR1 and positions 414, 431, and 453 in the 
E2 front layer have a concerted role in regulating broad NAb sen-
sitivity through perturbation of global conformation dynamics of 
E1/E2 between theoretical closed and open states. Closed E1/E2 
states are shown to depend on HVR1, explaining why HVR1 dele-
tion results in broad increases in NAb sensitivity (6), and to confer 
an increased need for SR-BI to prime subsequent CD81 interactions 
during entry. We uncover a link between global closed E1/E2 states 
and -hairpin–like conformations of AS412 providing a previously 
undescribed role of this flexible region in HCV NAb evasion, with im-
portant implications for targeting this highly conserved and linear 
E2 epitope in rational vaccine design.
During chronic infection, HCV accumulates mutations in the 
C terminus of HVR1 (32). This variation is believed to be mainly due 
to positive selection from HVR1-specific antibodies (9). However, 
we show that polymorphisms within positions 400 to 404 of HVR1 
broadly regulate NAb sensitivity with epitope-level differences, sug-
gesting that mutations may accumulate here to protect the virus from 
NAbs targeting non-HVR1 epitopes. We also found protective 
polymorphisms at positions 414, 431, and 453 outside of HVR1, which 
have a larger effect on AR3A sensitivity than AR4A sensitivity. Thus, 
our data indicate that HCV can fine-tune broad HCV neutralization 
sensitivity at the epitope level. Protective polymorphisms at 414, 
431, and 453 all overlap with resistance-associated envelope poly-
morphisms (RAPs) identified by analyzing correlates of NAb 
protection across a large collection of genotype 1 patient viruses 
(3, 33), further validating the importance of these positions in 
determining HCV isolate differences in NAb sensitivity and indicat-
ing broad applicability of our mechanistic findings.
The broad effects on NAb sensitivity of positions in HVR1 and 
the E2 front layer seemed analogous to the broad effects of deleting 
HVR1 (6) or genetically abolishing selected E2 glycosylation sites 
(7), which suggested that global dynamic rearrangements of E1/E2 
could be determining HCV isolate differences in NAb sensitivity. 
Performing temperature-dependent neutralization, we found that 
protective polymorphisms did indeed regulate broad NAb sensitivity 
by shifting global E1/E2 conformations from open (neutralization- 
sensitive) to closed (neutralization-resistant) states. We confirmed 
our prior findings that closed states were completely destabilized by 
the deletion of HVR1. This combines NAb evasion by HVR1, 
N-linked glycans, and RAPs at a mechanistic level while offering an 
attractive explanation for the breadth in increased NAb sensitivity 
of HVR1-deleted viruses (6). MD simulations on HCV E2c struc-
tures suggested that the polymorphic sites 431 and 453 altered the 
balance between open and closed states by affecting E2 front layer 
dynamics and suggested that these effects would also alter HVR1-
AS412 positioning. This in silico verification affirmed our experimental 
data. By linking sequence variability of E2 to global E1/E2 confor-
mational state dynamics, these findings have important implications 
for our understanding of HCV NAb evasion and suggest that suc-
cessful HCV vaccine development may depend on investigating the 
theoretical open and closed states of E1/E2 at a structural level.
To address why HCV would not evolve to predominantly adopt 
maximally closed and thus NAb-resistant E1/E2 states, we tested 
whether such a state might confer entry disadvantages. We observed 
strong correlations between NAb resistance and SR-BI dependency 
as also described before (33). A previous study on this phenomenon 
used sE2 to study SR-BI binding, which was higher in the presence 
of antibody when sE2s was derived from a NAb-resistant envelope 
sequence (33). However, sE2 does not fully recapitulate E1/E2 
dynamics on infectious particles as observed in this study and by 
others (34). In addition, SR-BI is most likely not a central attachment 
factor, which is primarily mediated by glycosaminoglycans (GAGs) (2), 
making it difficult to interpret how increased SR-BI binding might 
affect HCV entry. Our data confirm that SR-BI interaction occurs at 
a postattachment step, and the near-perfect correlation between SR-BI 
dependency and sCD81-LEL neutralization sensitivity suggests that 
SR-BI aids NAb-resistant HCV engage CD81, perhaps by mediating 
closed to open E1/E2 transitions. This previously undescribed role of 
SR-BI in HCV entry adds mechanistic context to a recent study in 
which a mathematical model of HCV entry kinetics was developed, 
suggesting that HCV interactions with CD81 can occur via two 
routes, either directly or with prior engagement of SR-BI (35). This 
has important implications for our understanding of HCV NAb 
evasion and provides a mechanism for the increased dependency 
on SR-BI of naturally NAb-resistant HCV isolates.
The importance of HVR1 in stabilizing closed E1/E2 states made 
us consider whether conformation of the highly flexible downstream 
region, AS412, would be associated with specific states. Thus, we 
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devised an approach using mAbs and Fabs targeting AS412 with 
similar conformational specificities and found that protective poly-
morphisms increased sensitivity to the smaller (e.g., better at pene-
trating closed E1/E2 states) FabAP33 relative to the larger (e.g., poorer 
penetration) mAbAP33. Thus, the conformational space of AS412 
appeared to be skewed toward -hairpin–like conformations (AP33 
binds to AS412 in a -hairpin) in closed E1/E2 states. As protective 
polymorphisms have been described at different positions in other 
isolates (3, 33), it is possible that they stabilize AS412 -hairpin con-
formation in a similar fashion. This was supported further by the 
finding that shifting the E1/E2 conformations toward open states, 
by increasing the temperature, consistently decreased FabAP33 
neutralization sensitivity (the opposite effect of what was observed 
for all tested NAbs and FabHC33.4). While it is not useful to probe 
HVR1-AS412 behavior on sE2, we instead investigated purely local 
effects of relevant polymorphisms by performing MD simulations 
of HVR1-AS412 peptides. We observed that protective polymor-
phisms at positions 400 to 404 and 414 had a stabilizing effect on 
AS412 -hairpin conformation, while sensitizing polymorphisms at 
the same positions caused its disruption. Intriguingly, the results 
suggested a direct -sheet interaction between the C terminus of 
HVR1 and AS412, which would be of interest for future studies. 
Our findings match well with a recent report that HCV escape 
mutants, which developed epitope-specific resistance against mAbs 
targeting the -hairpin conformation of AS412, had increased 
sensitivity to bNAbs targeting other epitopes (36). By linking the 
local structural flexibility of AS412 to global E1/E2 conformational 
state, we show that AS412 flexibility is linked directly to broad HCV 
NAb evasion function.
AS412 is a highly conserved neutralization epitope (10), and the 
fact that it is linear makes it directly amenable to antigen mimicry 
for rational vaccine development (15–17). This allows for the pre-
sentation of AS412 without undesirable off-targets, which can help 
limit the induction of non-neutralizing or interfering antibodies. 
NAbs that recognize the AS412 -hairpin conformation have shown 
efficacy in vivo (18, 37). However, these antibodies have a low barrier 
to resistance (36), which is why it has been suggested to instead target 
the intermediate V-shaped AS412 conformation, which is recognized 
by potent members of the HC33 group of NAbs, for which escape 
has not been reported (38). However, our study indicates that AS412 
diversity is not merely a viral mechanism for avoiding immune rec-
ognition, but rather that diverse AS412 conformations are func-
tionally distinct with important roles in regulating the global E1/E2 
conformational state and thus also broad viral NAb sensitivity. This 
has important implications for rational vaccine design such as suggest-
ing that AS412 antigen mimicry should not be focused on a single 
conformation but rather aim at including all function-relevant 
AS412 conformations, most notably the -hairpin and the V-shaped, 
to obtain broad high-level protection.
In conclusion, our study shows that broad differences in NAb 
sensitivity between HCV isolates are mediated indirectly by protec-
tive polymorphisms within and outside HVR1 by modulation of 
epitope accessibility through shifting E1/E2 conformations between 
open (neutralization-sensitive) and closed (neutralization-resistant) 
states. The variation in this effect across NAb epitopes provides an 
alternative rationale for the extraordinary sequence diversity of HVR1, 
other than direct immune escape, by supporting that positions 400 
to 404 within HVR1 accumulate substitutions to fine-tune accessi-
bility of non-HVR1 epitopes as they become targeted by the host 
immune system. The effects of these polymorphisms on protein 
dynamics are not fully recapitulated on sE2, which is likely due to 
the importance of unknown interactions within the E1/E2 heterodimer 
and potentially even on interactions with nonenvelope moieties, such 
as apolipoprotein E (ApoE) (39). Inherently NAb resistant HCV 
has an increased dependency on SR-BI. Our data suggest that this 
SR-BI interaction mediates E1/E2 transitions from closed to open, 
poised for CD81 engagement. The link between local AS412 conform-
ation and global E1/E2 state has important implications for targeting 
AS412 in rational vaccine designs, and the implied influence of 
AS412 conformation on E1/E2 structural dynamics suggests a weak-
ness in HCV NAb evasion that could be exploited in the design of 
new antivirals. Specifically, compounds that prevent AS412 from 
adopting -hairpin–like conformations could stabilize an open E1/
E2 state, similar to how Winthrop compounds prevent structural 
transitions in picornaviruses (40). Overall, our study represents key 
advancements in our understanding of HCV NAb evasion in viral 
persistence with important implications for rational vaccine design.
MATERIALS AND METHODS
Cell lines
Huh7.5 cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco/Invitrogen Corporation, Carlsbad, CA) supplemented 
with 10% of heat-inactivated fetal bovine serum, penicillin (100 U/ml), 
and streptomycin (100 g/ml) (Gibco/Invitrogen Corporation) with 
5% CO2 at 37°C. Cells were split with trypsin-EDTA every 48 to 
72 hours.
Virus isolates
We used previously described HCV recombinants with Core-NS2 
of isolates H77C, TN, J4, J6, J8, or S52 and untranslated regions and 
NS3-NS5B of JFH1 (20–22, 24). HVR1 sequences were of isolates 
TN, DH1, DH5, J4, J6, S52, ED43, SA13, and HK6a (20, 21, 23, 25). 
All virus recombinants are referred to in the manuscript by their 
E1/E2 sequence. We introduced HVR1 sequences and coding 
mutations into the indicated recombinants by standard molecular 
cloning techniques (QuikChange). Each plasmid was confirmed by 
sequencing the entire HCV sequence of the final DNA preparation 
(Macrogen).
Source of antibodies and sCD81-LEL
mAbs used for neutralization assays were specific for antigenic 
regions 2 to 5 (AR2A, AR3A, AR4A, and AR5A), domain D 
(HC84.26), or AS412 (AP33, HC33.4, and 3/11) with control anti-
body b6 (27, 28, 34, 41–44). AP33, HC33.4, and 3/11 Fab fragments 
used in neutralization assays or ELISA were prepared as described 
(45). sCD81-LEL was also used for neutralization assays (41) and 
ELISA (R&D Systems, catalog no.9144-CD). For receptor blocking 
assays, we used anti-CD81 (BD Pharmingen, catalog no.JS81), anti–
SR-BI C16-71 (46, 47), or anti-LDLr 3D8 (48) with the control anti-
bodies 553447 for CD81 and antibody D for SR-BI (46) and a previously 
described in-house produced isotype-matched control for LDLr (48).
Transfection of Huh7.5 cells
HCV transfections were done as described (47). Briefly, Xba I– 
linearized plasmids were used to generate HCV RNA transcripts that 
were transfected into Huh7.5 cells using Lipofectamine 2000. Viral 
spread and release of infectious particles were monitored every day 
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in 4-day transfection assays, by immunostaining of transfected cells 
and analysis of HCV infectivity titers in supernatants. Immunostaining 
was done with anti-NS5A antibody 9E10 (24) and with secondary 
anti-mouse Alexa Fluor 488 goat anti-mouse immunoglobulin G 
(IgG; Invitrogen). Hoechst 33342 dye was used for fluorescent 
staining of cells. HCV infectivity titrations were performed in trip-
licate by plating 7 × 103 Huh7.5 cells in poly-d-lysine 96-well plates 
and incubating them for 24 hours. The following day, different di-
lutions of virus supernatant were incubated 10 min at 37°C in 5% 
CO2 before addition to Huh7.5 cells and incubation of 48 hours at 
37°C in 5% CO2. Fixation and staining of HCV-positive cells and 
counting of the number of focus-forming units (FFUs) were done 
as described (22, 49).
Generation of first-passage virus stocks
First-passage virus stocks of HCVcc recombinants were generated 
by passaging transfection supernatants onto naïve Huh7.5 cells and 
culturing these by splitting the cells every 2 to 3 days until the virus 
spread to >80% of the cells (9 to 20 days). At this time, supernatant 
was harvested and filtered and the virus analyzed by infectivity 
titration and sequencing of the envelope-encoding sequence of 
culture-derived HCV RNA as described (49).
Expression of soluble E2
A truncated, soluble form of E2 ectodomain (sE2) (amino acids 384 
to 645) with a C-terminal His tag, following the 30 C-terminal amino 
acids of E1 that includes a peptidase cleavage site and ensures efficient 
protein secretion, was transfected in human embryonic kidney 293 
T cells as described (50). Supernatant was collected at 48 and 72 hours, 
filtered, and concentrated using an Amicon Ultra-15 Centrifugal 
Filter Unit (10-kDa cutoff). Quantification of the relative concen-
tration in the collected supernatants was done as described (50) and 
used to normalize the sE2 input in ELISAs.
Antibody neutralization
A total of 7 × 103 Huh7.5 cells were plated per well in poly-d-lysine 
96-well plates and incubated for 24 hours with 5% CO2 at 37°C. The 
following day, a dilution series of mAb and relevant control anti-
body were incubated with a volume of virus stock corresponding to 
a readout of 50 to 200 FFU per well in four replicates of each dilution 
step. The antibody-virus mixtures were, along with eight replicates 
of virus only, incubated for 1 hour at 37°C before addition to Huh7.5 cells 
and incubation for 4 hours at 37°C in 5% CO2. Cells were washed, 
and fresh medium was added before incubation for a total infection 
time of 48 hours before fixation. Staining and counting of the num-
ber of FFUs were done as described (22, 49), with primary antibody 
9E10 and secondary antibody ECL Anti-mouse IgG, Horseradish 
Peroxidase using the 3,3′-diaminobenzidine (DAB) staining kit. The 
data were normalized to the eight replicates of virus only and analyzed 
using three or four parameters curve fitting in GraphPad Prism 8.0.0, 
bottom set to 0, top set to 100, with values reported as means ± SD.
Temperature-dependent neutralization
This assay was done as described above for the antibody neutraliza-
tion assay with the differences outlined below. We used a threefold 
higher input of virus per well when we tested effects of temperature 
on neutralization (to attain a similar number of FFUs per well), with 
three replicates of each dilution step and six replicates of virus only. 
Virus/antibody were incubated for 1 hour at either 4°, 37°, or 40°C, 
and the antibody-virus mixtures were spinoculated onto the cells at 
500 rcf for 2 hours at 4°C. Cells were washed with cold phosphate- 
buffered saline (PBS) buffer, and prechilled DMEM was added 
before raising the temperature to 37°C for a total infection time of 
48 hours. Fixation, counting, and data analysis were performed as 
described for antibody neutralization.
HCV soluble E2 ELISA
Pierce Nickel Coated Plates (Thermo Fisher Scientific) were incubated 
overnight at 4°C with equivalent amount of sE2. The following day, 
a dilution series of mAbs or soluble receptor were incubated 1 hour 
at room temperature in two replicates of each dilution step. Plates 
were washed and binding was detected with horseradish peroxidase– 
conjugated anti-human IgG secondary antibody (Thermo Fisher 
Scientific).
Receptor blocking
Huh7.5 cells were plated as described above for antibody neutralization. 
The following day, cells were incubated 1 hour at 37°C with anti-
receptor antibodies (46, 47, 51) or respective control antibodies (46, 48). 
Then, virus was added to the cells in four replicates of each dilution 
step and eight replicates of virus only followed by 4-hour incubation. 
Cells were washed, and fresh medium was added before incubation 
for a total infection time of 48 hours. Fixation, counting, and data 
analysis were performed as described for antibody neutralization.
Receptor blocking before and after attachment
Huh7.5 cells were plated as described above for antibody neutraliza-
tion. The following day, a virus input sixfold higher than described 
above for receptor blocking was spinoculated onto the cells at 500 rcf 
for 1 hour at 4°C, with six replicates for each antibody tested and 
six replicates of virus only. Cells were washed with cold PBS buffer 
and antireceptor antibodies (46, 47) were added before a second 
spinoculation at 500 rcf for 1 hour at 4°C. Cells were washed, and 
fresh medium was added before incubation at 37°C for a total infection 
time of 48 hours. Fixation, counting, and normalization were per-
formed, as described for antibody neutralization, with values reported 
as means ± SEM.
Quantification and statistical analysis
The neutralization data were analyzed using three- or four-parameter 
dose-response curves to calculate IC50 values and 95% confidence 
intervals (GraphPad Prism 8.0.0). The receptor blocking data were 
analyzed using three-parameter dose-response curves to estimate 
maximum attainable effect, Bmax, which is defined as the percentage 
blocking of entry that curve-fitting asymptotically approaches. IC50 
and Bmax values for HCV recombinants were compared with the 
relevant unmodified recombinant (neutralization assay and receptor 
blocking assay) or with IC50 values at 37°C (temperature-dependent 
neutralization assay) in two-tailed t tests (GraphPad Prism 8.0.0) 
with Welch’s correction, not assuming equal SDs. Testing was done 
at the 95% confidence level (*P < 0.05, **P < 0.01, and ***P < 0.001) 
and corrected for multiple testing by adjusting the P value accordingly. 
IC50 values for HCV recombinants with the same HVR1 sequence 
were compared using one-way ANOVA.
Structural modeling and MD simulations
E2 HVR1-AS412 (residues 384 to 426) tested sequences were fed to 
the RaptorX server for secondary and tertiary structure prediction 
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(52). Predicted structural features were converted into distance and 
angle restraints as previously described (53) and applied to each sys-
tem linear structure using the standard distance geometry/simulated 
annealing protocol implemented in CNS (Crystallography and NMR 
System, version 1.3) to obtain HVR1-AS412 initial models (54).
Wild-type H77, S52, and TN and mutant H77TN_431/453 E2c (residues 
421 to 647) initial structures were reconstructed with MODELLER 
using the Protein Data Bank structures with ID 6MEI and 6MEJ as 
templates. AS412 was not included to avoid potential non-native 
interactions due to the absence of HVR1 in both crystal structures.
Both HVR1-AS412 peptides and E2c structures were simulated 
in an orthorhombic TIP3P water box, neutralized with the proper 
counterions, and parametrized using the all-atom AMBER/parm12SB 
force field (55). All simulations were performed using the GROMACS 
5.1.4 code (56). Periodic boundary conditions in the three axes were 
applied. Covalent bond length, including hydrogen bonds, was set 
using the LINCS algorithm, allowing a time-integration step of 2 fs. 
Constant pressure was imposed using the Parrinello-Rahman barostat 
with a time constant of 2 ps and a reference pressure of 1 bar, while 
constant temperature was maintained using the modified Berendsen 
thermostat with a time constant of 0.1 ps. Long-range electrostatic 
interactions were calculated with the particle mesh Ewald method 
with a real-space cutoff of 12 Å. Each system was minimized with 
the steepest descent algorithm, equilibrated for 100 ps in an NVT 
ensemble followed by 100 ps in an NPT ensemble and then subjected 
to a 500-ns simulation at constant temperature (300 K). For high- 
temperature (450 K) simulations, the most visited structure for each 
system, identified by PCA and FEL calculation on each 500-ns 
trajectory, was used as the starting point. The temperature was in-
creased in four steps from 300 to 450 K over 1 ns, and then each 
system was simulated at 450 K for 10 ns.
All analyses, including PCA, FEL, SASA, and root mean square 
fluctuation calculations, were performed using the tools implemented 
in GROMACS and VMD (Visual Molecular Dynamics, version 1.9.3). 
Structure rendering was performed in VMD (57).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/35/eabb5938/DC1
View/request a protocol for this paper from Bio-protocol.
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